Novartis Ag Adr Stock Today

NVS Stock  USD 113.77  0.70  0.61%   

Performance

7 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Less than 5

 
High
 
Low
Very Low
Novartis is selling for under 113.77 as of the 3rd of October 2024; that is 0.61% down since the beginning of the trading day. The stock's lowest day price was 113.68. Novartis has under 5 % chance of experiencing financial distress over the next 2 years but had a somewhat ok performance during the last 90 days. Note, on May 19, 2024, Senator Sheldon Whitehouse of US Senate acquired under $15k worth of Novartis AG ADR's common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
18th of November 1991
Category
Healthcare
Classification
Health Care
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 2.02 B outstanding shares of which 5.32 M shares are now shorted by investors with about 5.08 days to cover. More on Novartis AG ADR

Moving together with Novartis Stock

  0.74BMY Bristol Myers Squibb Aggressive PushPairCorr

Moving against Novartis Stock

  0.82ESPR Esperion Therapeutics Buyout TrendPairCorr
  0.73CPIX Cumberland PharmaceuticalsPairCorr
  0.7RLYB Rallybio CorpPairCorr
  0.66CDT Conduit PharmaceuticalsPairCorr
  0.64CYTHW Cyclo TherapeuticsPairCorr
  0.59MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr

Novartis Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEORichard Saynor
Thematic Ideas
(View all Themes)
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, Compulsion, Healthcare, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Return On Assets0.110.1486
Way Down
Pretty Stable
Asset Turnover0.520.4669
Moderately Up
Pretty Stable
Gross Profit Margin0.780.7327
Notably Up
Slightly volatile
Net Debt11 B13 B
Fairly Down
Slightly volatile
Total Current Liabilities22 B26.4 B
Fairly Down
Slightly volatile
Non Current Liabilities Total23.6 B26.8 B
Fairly Down
Slightly volatile
Total Assets103.1 B99.9 B
Sufficiently Up
Pretty Stable
Total Current Assets29.9 B30.5 B
Fairly Down
Slightly volatile
Total Cash From Operating Activities11.7 B14.5 B
Significantly Down
Slightly volatile
Debt Levels
Novartis can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Novartis' financial leverage. It provides some insight into what part of Novartis' total assets is financed by creditors.
Liquidity
Novartis AG ADR has 26.35 B in debt with debt to equity (D/E) ratio of 0.47, which is OK given its current industry classification. Novartis AG ADR has a current ratio of 1.28, demonstrating that it may not be capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Novartis to invest in growth at high rates of return.

Capital Expenditures

2.59 Billion
Novartis AG ADR (NVS) is traded on New York Stock Exchange in USA. It is located in Lichtstrasse 35, Basel, Switzerland, 4056 and employs 76,057 people. Novartis is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 231.92 B. Novartis AG ADR runs under Pharmaceuticals sector within Health Care industry. The entity has 2.02 B outstanding shares of which 5.32 M shares are now shorted by investors with about 5.08 days to cover. Novartis AG ADR has about 4.64 B in cash with 14.46 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.84.
Check Novartis Probability Of Bankruptcy
Ownership Allocation
Novartis AG ADR maintains a total of 2.02 Billion outstanding shares. Roughly 93.08 % of Novartis outstanding shares are held by general public with 6.92 % by institutional investors. Please note that on May 19, 2024, Senator Sheldon Whitehouse of US Senate acquired under $15k worth of Novartis AG ADR's common stock.
Check Novartis Ownership Details

Novartis Stock Institutional Holders

InstituionRecorded OnShares
Renaissance Technologies Corp2024-06-30
2.5 M
Principal Financial Group Inc2024-06-30
2.5 M
Wells Fargo & Co2024-06-30
2.1 M
Northern Trust Corp2024-06-30
2.1 M
Envestnet Asset Management Inc2024-06-30
1.9 M
Bank Of New York Mellon Corp2024-06-30
1.9 M
Blackrock Inc2024-06-30
1.9 M
State Street Corp2024-06-30
1.8 M
Fisher Asset Management, Llc2024-06-30
1.5 M
Dodge & Cox2024-06-30
12.2 M
Primecap Management Company2024-06-30
12.2 M
View Novartis Diagnostics

Novartis Historical Income Statement

At this time, Novartis' Discontinued Operations is comparatively stable compared to the past year. Net Income From Continuing Ops is likely to gain to about 10.8 B in 2024, whereas Selling And Marketing Expenses is likely to drop slightly above 12.8 B in 2024. View More Fundamentals

Novartis Stock Against Markets

Novartis Corporate Directors

Ton BuechnerNon-Executive Independent DirectorProfile
Frans HoutenNon-Executive Independent DirectorProfile
Nancy AndrewsNon-Executive Independent DirectorProfile
Elizabeth DohertyNon-Executive Independent DirectorProfile

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.